glp 1 peptid GLP-1 Receptor Agonist Services for Type 2 Diabetes and Obesity Drug Development GLP-1 Medications – Community Education

In a randomized controlled trial targeting type 2 diabetes mellitus patients with chronic kidney disease, Astragalus administration significantly reduced fasting blood glucose and HbA1c levels and improved insulin resistance (Chan et al., 2024)

250ML-07/31/2021

Similarly, alcohol and caffeine consumption close to bedtime may irritate the stomach lining or trigger acid reflux symptoms

As the prevalence of obesity rises, so do related chronic conditions such as diabetes, heart disease and hypertension, creating a massive market for treatments like GLP-1 drugs

Simply contact our Tucson office to schedule your free, no-obligation consultation